Listed

BioLineRx Ltd.: Form 20-F for the period ended Dec 31, 2019

Filed with the SEC on Mar 12, 2020 and accepted by EDGAR at Mar 12, 2020, 11:07 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income12 months2019-01-01 to 2019-12-31−$28.1mifrs-full:ProfitLossFromOperatingActivities
Net income12 months2019-01-01 to 2019-12-31−$25.4mifrs-full:ProfitLoss
Operating cash flow12 months2019-01-01 to 2019-12-31−$22.7mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2019-01-01 to 2019-12-31$67.0kifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2019-12-31$5.3mifrs-full:CashAndCashEquivalents
Current assetsAt period end2019-12-31$28.2mifrs-full:CurrentAssets
Total assetsAt period end2019-12-31$53.6mifrs-full:Assets
Current liabilitiesAt period end2019-12-31$12.0mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2019-12-31$20.2mifrs-full:Liabilities
Shareholders' equityAt period end2019-12-31$33.4mifrs-full:Equity
Shares outstandingAt period end2019-12-31171,269,528 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001178913-20-000790. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.